Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects
- 1 October 2000
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 4 (5) , 609-633
Abstract
A major hallmark of malignant disease is the capacity of cancer cells to cross tissue boundaries and spread to distant sites throughout the body. Extracellular matrix-degrading enzymes are thus required to break down structural barriers to invasion and metastasis. Extensive and compelling evidence indicates that several members of the matrix metalloproteinase (MMP) family of enzymes play a key role in this regard and forms the rationale for the development and testing of compounds that can inhibit their proteolytic activity. In addition, data now indicate that MMPs contribute to other aspects of cancer, including angiogenesis and the initial stages of tumour development, thus expanding the potential clinical utility of MMP inhibitors (MMPIs). Conversely, some MMPs may defy cancer progression and others may not participate in cancer, but undoubtedly play normal physiologic roles. These possibilities and the mechanisms underlying the influence of MMPs in cancer must be understood and considered in the desig...Keywords
This publication has 129 references indexed in Scilit:
- Post-translational Proteolytic Processing of Procollagen C-terminal Proteinase Enhancer Releases a Metalloproteinase InhibitorJournal of Biological Chemistry, 2000
- Cancer biology: Extracellular proteinases in malignancyCurrent Biology, 1999
- Gelatinase A-Immunoreactive Protein in Ovarian Lesions— Prognostic Value in Epithelial Ovarian CancerGynecologic Oncology, 1999
- Matrix Metalloproteinase 2 Immunoreactive Protein Appears Early in Cervical Epithelial DedifferentiationGynecologic Oncology, 1999
- Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family MembersJournal of Biological Chemistry, 1999
- TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3FEBS Letters, 1998
- Expression of Autoactivated Stromelysin-1 in Mammary Glands of Transgenic Mice Leads to a Reactive Stroma During Early DevelopmentThe American Journal of Pathology, 1998
- Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastatEuropean Journal of Cancer, 1997
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Tissue inhibitor of metalloproteinase‐2 (TIMP‐2) has erythroid‐potentiating activityFEBS Letters, 1992